FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254. PMID:25559415.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28. doi:10.1038/nrc2644. PMID:19461667.
   PubMed Web of Science ®Google Scholar
• Longuespee R, Boyon C, Desmons A, Vinatier D, Leblanc E, Farre I, Wisztorski M, Ly K, D'Anjou F, Day R, et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev. 2012;31:713–32. doi:10.1007/s10555-012-9383-7. PMID:22729278.
   PubMed Web of Science ®Google Scholar
• Fan G, Zhang S, Gao Y, Greer PA, Tonks NK. HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer. Genes Dev. 2016;30:1542–57. doi:10.1101/gad.284166.116. PMID:27401557.
   PubMed Web of Science ®Google Scholar
• Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev. 2004;18:2225–30. doi:10.1101/gad.317604. PMID:15371335.
   PubMed Web of Science ®Google Scholar
• Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, Duñach M. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol. 2003;23:2287–97. doi:10.1128/MCB.23.7.2287-2297.2003. PMID:12640114.
   PubMed Web of Science ®Google Scholar
• Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, Lilien J, Balsamo J. Continuous association of cadherin with beta-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci. 2004;117:3207–19. doi:10.1242/jcs.01174. PMID:15226396.
   PubMed Web of Science ®Google Scholar
• Giordano S, Bardelli A, Zhen Z, Menard S, Ponzetto C, Comoglio PM. A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci U S A. 1997;94:13868–72. doi:10.1073/pnas.94.25.13868. PMID:9391119.
   PubMed Web of Science ®Google Scholar
• Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci. 2012;125:2940–53. doi:10.1242/jcs.100834. PMID:22366451.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010;16:699–710. doi:10.1158/1078-0432.CCR-09-1365. PMID:20068101.
   PubMed Web of Science ®Google Scholar
• Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16:37–45. doi:10.1016/j.molmed.2009.11.005. PMID:20031486.
   PubMed Web of Science ®Google Scholar
• Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010;70:7580–90. doi:10.1158/0008-5472.CAN-10-0436. PMID:20841479.
   PubMed Web of Science ®Google Scholar
• Petti C, Picco G, Martelli ML, Trisolini E, Bucci E, Perera T, Isella C, Medico E. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget. 2015;6:221–33. doi:10.18632/oncotarget.2771. PMID:25473895.
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103. doi:10.1038/nrc3205. PMID:22270953.
   PubMed Web of Science ®Google Scholar
• Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9:690–701. doi:10.1038/nrm2476. PMID:18719708.
   PubMed Web of Science ®Google Scholar
• Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69. doi:10.1146/annurev.cellbio.21.020604.150721. PMID:16212495.
   PubMed Web of Science ®Google Scholar
• Garcia-Bernal D, Wright N, Sotillo-Mallo E, Nombela-Arrieta C, Stein JV, Bustelo XR, Teixidó J. Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1. Mol Biol Cell. 2005;16:3223–35. doi:10.1091/mbc.E04-12-1049. PMID:15872091.
   PubMed Web of Science ®Google Scholar
• Boettner B, Van Aelst L. Control of cell adhesion dynamics by Rap1 signaling. Curr Opin Cell Biol. 2009;21:684–93. doi:10.1016/j.ceb.2009.06.004. PMID:19615876.
   PubMed Web of Science ®Google Scholar
• Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994;367:40–6. doi:10.1038/367040a0. PMID:8107774.
   PubMed Web of Science ®Google Scholar
• Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell. 2000;102:387–97. doi:10.1016/S0092-8674(00)00043-X. PMID:10975528.
   PubMed Web of Science ®Google Scholar
• Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28:2545–55. doi:10.1038/onc.2009.119. PMID:19465939.
   PubMed Web of Science ®Google Scholar
• Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene. 2016;35:2178–85. doi:10.1038/onc.2015.278. PMID:26257058.
   PubMed Web of Science ®Google Scholar
• Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, et al. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene 2012;31:3397–408.
   Google Scholar
• Brown LA, Kalloger SE, Miller MA, Shih Ie M, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 2008;47:481–9. doi:10.1002/gcc.20549. PMID:18314909.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G. Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 2008;10:R81. doi:10.1186/bcr2150. PMID:18823530.
   PubMed Web of Science ®Google Scholar
• Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, Bokoch GM. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol. 2000;20:453–61. doi:10.1128/MCB.20.2.453-461.2000. PMID:10611223.
   PubMed Web of Science ®Google Scholar
• Motwani M, Li DQ, Horvath A, Kumar R. Identification of novel gene targets and functions of p21-activated kinase 1 during DNA damage by gene expression profiling. PloS One. 2013;8:e66585. doi:10.1371/journal.pone.0066585. PMID:23950862.
   PubMed Web of Science ®Google Scholar
• Fei F, Kweon SM, Haataja L, De Sepulveda P, Groffen J, Heisterkamp N. The Fer tyrosine kinase regulates interactions of Rho GDP-Dissociation Inhibitor alpha with the small GTPase Rac. BMC Biochem. 2010;11:48. doi:10.1186/1471-2091-11-48. PMID:21122136.
   PubMed Web of Science ®Google Scholar
• Itoh T, Hasegawa J, Tsujita K, Kanaho Y, Takenawa T. The tyrosine kinase Fer is a downstream target of the PLD-PA pathway that regulates cell migration. Sci Signal. 2009;2:ra52. doi:10.1126/scisignal.2000393. PMID:19738202.
   PubMed Web of Science ®Google Scholar
• Ahn J, Truesdell P, Meens J, Kadish C, Yang X, Boag AH, Craig AW. Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis. Mol Cancer Res. 2013;11:952–63. doi:10.1158/1541-7786.MCR-13-0003-T. PMID:23699534.
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–203. doi:10.1016/j.cell.2007.11.025. PMID:18083107.
   PubMed Web of Science ®Google Scholar
• Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, Xue T, Shen Y, Liu Y. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer. 2009;9:366. doi:10.1186/1471-2407-9-366. PMID:19835603.
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res. 2009;7:142–55. doi:10.1158/1541-7786.MCR-08-0117. PMID:19147545.
   PubMed Web of Science ®Google Scholar
• Albeck JG, Brugge JS. Uncovering a tumor suppressor for triple-negative breast cancers. Cell. 2011;144:638–40. doi:10.1016/j.cell.2011.02.030. PMID:21376226.
   PubMed Web of Science ®Google Scholar
• Ren H, Tan ZP, Zhu X, Crosby K, Haack H, Ren JM, Beausoleil S, Moritz A, Innocenti G, Rush J, et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res. 2012;72:3312–23. doi:10.1158/0008-5472.CAN-11-3931. PMID:22570254.
   PubMed Web of Science ®Google Scholar
• Greer P. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell biol. 2002;3:278–89. doi:10.1038/nrm783. PMID:11994747.
   PubMed Web of Science ®Google Scholar
• Craig AW. FES/FER kinase signaling in hematopoietic cells and leukemias. Front Biosci (Landmark Ed). 2012;17:861–75. doi:10.2741/3961. PMID:22201778.
   PubMed Web of Science ®Google Scholar